Brief: Innate Pharma Flags Positive Data From AstaZeneca's Monalizumab Study

Innate Pharma SA

17/09/2021 12:48

Sept 17 (Reuters) - Innate Pharma SA  IPH.PA :
    * MONALIZUMAB DATA FROM COAST TRIAL PRESENTED AT ESMO
CONGRESS
2021
    * RESULTS SHOWED MONALIZUMAB IN COMBINATION WITH DURVALUMAB
IMPROVED PROGRESSION-FREE SURVIVAL AND OBJECTIVE RESPONSE RATE
VERSUS DURVALUMAB ALONE
    * ASTRAZENECA INFORMED INNATE IT PLANS TO START
REGISTRATIONAL
STUDY WITH MONALIZUMAB IN COMBINATION WITH DURVALUMAB FOR
UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER

Source text for Eikon:  ID:nGNX3jHxyg 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))